

Ligufalimab

Cat. No.:	HY-P99706
CAS No.:	2428381-55-7
Target:	Interleukin Related
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Ligufalimab (AK 117) is a humanized IgG4 anti-CD47 monoclonal antibody. Ligufalimab does not induce RBC hemagglutination, and induces phagocytosis. Ligufalimab shows anti-tumor activity ^[1] .								
In Vitro	Ligufalimab binds to human CD47 antigen with an EC ₅₀ value of 0.078 nM, K _D value of 0.152 nM ^[1] . Ligufalimab (0-3000 nM) does not induce RBC hemagglutination ^[1] . Ligufalimab (0.1, 1, 10 µg/mL) induces phagocytosis of Raji, Jurkat and Ramos cells in a dose-dependent manner ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
In Vivo	Ligufalimab (0.1, 1 mg/kg for Raji xenograft, 0.2 mg/kg for MDA-MB-231 xenograft model) inhibits tumor growth in mice ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
	<table border="1"> <tr> <td>Animal Model:</td> <td>SCID/Beige mice (Raji xenograft model, MDA-MB-231 xenograft model)^[1]</td> </tr> <tr> <td>Dosage:</td> <td>0.1, 1 mg/kg for Raji xenograft, 0.2 mg/kg for MDA-MB-231 xenograft model</td> </tr> <tr> <td>Administration:</td> <td>I.v.</td> </tr> <tr> <td>Result:</td> <td>Inhibited tumor growth with the tumor inhibition rate of 88.56%, 63.78% at 1, 0.1 mg/kg.</td> </tr> </table>	Animal Model:	SCID/Beige mice (Raji xenograft model, MDA-MB-231 xenograft model) ^[1]	Dosage:	0.1, 1 mg/kg for Raji xenograft, 0.2 mg/kg for MDA-MB-231 xenograft model	Administration:	I.v.	Result:	Inhibited tumor growth with the tumor inhibition rate of 88.56%, 63.78% at 1, 0.1 mg/kg.
Animal Model:	SCID/Beige mice (Raji xenograft model, MDA-MB-231 xenograft model) ^[1]								
Dosage:	0.1, 1 mg/kg for Raji xenograft, 0.2 mg/kg for MDA-MB-231 xenograft model								
Administration:	I.v.								
Result:	Inhibited tumor growth with the tumor inhibition rate of 88.56%, 63.78% at 1, 0.1 mg/kg.								

REFERENCES

[1]. Qu T, et al. Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity. J Immunother Cancer. 2022 Nov;10(11):e005517.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA